Elimination of cervical cancer as a public health problem-how shorter brachytherapy could make a difference during COVID-19.

COVID-19 pandemic brachytherapy cervix uteri radiation dose fractionation

Journal

Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236

Informations de publication

Date de publication:
2022
Historique:
received: 30 09 2021
entrez: 5 5 2022
pubmed: 6 5 2022
medline: 6 5 2022
Statut: epublish

Résumé

The World Health Organization has called for elimination of cervical cancer as a public health problem and has adopted strategies in this regard. However, the estimates for achieving the goals depend on the ability to provide timely treatment in a certain proportion of cases. The coronavirus disease 2019 pandemic has had a serious impact on healthcare delivery in many low and middle income countries (LMICs) with the highest burden of cervical cancer; funds and infrastructure are being reallocated to deal with the emergency, and cancer care has been seriously affected. In the absence of clear and reliable estimates, the exact extent of disruption remains unclear. It is, therefore, essential that pragmatic approaches are adopted to save lives. There has been considerable debate regarding the use of the 9 Gy × 2 fractions high dose rate brachytherapy schedule for the treatment of locally advanced cervical carcinoma. However, in LMICs with the highest global burden of locally advanced cervical cancer cases, radiation facilities have been using this fractionation schedule in many cases to deal with the overwhelming number of patients, who would have otherwise been denied timely treatment. In view of the current pandemic, and the difficulties in accessing and delivering timely healthcare, mortality owing to delayed treatment cannot be denied in LMICs, which already have underequipped healthcare facilities. Use of the shortest available fractionation schedule to provide timely treatment would serve to save more lives in regions with high incidence and mortality from the disease.

Identifiants

pubmed: 35510136
doi: 10.3332/ecancer.2022.1352
pii: can-16-1352
pmc: PMC9023303
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1352

Informations de copyright

© the authors; licensee ecancermedicalscience.

Déclaration de conflit d'intérêts

None.

Références

Brachytherapy. 2012 Jan-Feb;11(1):47-52
pubmed: 22265437
JMIR Cancer. 2020 Oct 29;6(2):e21697
pubmed: 33027039
Int J Cancer. 2021 Jul 1;149(1):97-107
pubmed: 33533501
Radiother Oncol. 2020 Sep;150:191-194
pubmed: 32621832
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
Lancet Oncol. 2021 Apr;22(4):411
pubmed: 33794199
Front Oncol. 2016 Jun 28;6:160
pubmed: 27446806
J Contemp Brachytherapy. 2019 Oct;11(5):428-435
pubmed: 31749851
BMC Womens Health. 2020 Oct 7;20(1):225
pubmed: 33028336
Brachytherapy. 2020 Jul - Aug;19(4):390-400
pubmed: 32423787
J Clin Oncol. 2018 Jun 1;36(16):1548-1555
pubmed: 29432076
JCO Glob Oncol. 2020 Jul;6:1063-1075
pubmed: 32673076
Science. 2020 Jun 19;368(6497):1290
pubmed: 32554570
Front Oncol. 2015 Jan 22;4:380
pubmed: 25657930
Ecancermedicalscience. 2020 May 08;14:1040
pubmed: 32565893
Ecancermedicalscience. 2020 Apr 20;14:1026
pubmed: 32346392
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
Ecancermedicalscience. 2020 Jul 07;14:ed103
pubmed: 32728388
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Community Health. 2013 Oct;38(5):976-93
pubmed: 23543372
Asian Pac J Cancer Prev. 2015;16(16):7167-70
pubmed: 26514507
J Glob Health. 2021 Apr 17;11:03067
pubmed: 33884189
Front Oncol. 2021 May 17;11:675038
pubmed: 34079764
Radiother Oncol. 2005 Mar;74(3):235-45
pubmed: 15763303
Brachytherapy. 2019 Jul - Aug;18(4):429-436
pubmed: 30979631
JCO Glob Oncol. 2020 Jun;6:906-912
pubmed: 32589462
Cancer. 2006 Sep 1;107(5):908-15
pubmed: 16874815
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):702-6
pubmed: 12062615
Lancet Glob Health. 2018 Nov;6(11):e1196-e1252
pubmed: 30196093
JCO Glob Oncol. 2021 May;7:716-725
pubmed: 33999708
Nat Cancer. 2020 Jun;1(6):565-567
pubmed: 35121972

Auteurs

Aparna Gangopadhyay (A)

Independent Practice, 377, M. B. Road, Panchanantala, Kolkata 700049, India.

Classifications MeSH